Overview

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

This is a monocenter, single-arm, open label phase II trial evaluating the effect of SOM230 LAR in adult patients with inoperable primary thymoma and thymoma metastasis (Masaoka II-IVa). SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks. The purpose of this trial is a proof of concept.

Phase:

Phase 2

Details

Lead Sponsor:

Prof. Dr. Berthold Schalke

Collaborator:

Crolll Gmbh

Treatments:

Pasireotide